{"url_path":"/sec/engn/8-k/2026-06-18/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-275815-index.html","accession_number":"0001193125-26-275815","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-275815-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":308,"has_tables":true,"body_markdown":"## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nThe information set forth in Item 2.05 of this Current Report on Form 8-K/A is incorporated herein by reference as if set forth herein.\n\nOn June 16, 2026, the Compensation Committee approved the issuance of a performance-based retention option award to Ronald Cooper, Chief Executive Officer and President, consisting of non-qualified stock options to purchase 400,000 of the Company’s common shares at an exercise price per share of $1.75, the closing price of the Company’s common shares on the date of the grant (the “Executive Performance Option”). In alignment with the form and terms of the performance-based retention options, the Executive Performance Option will vest, if at all, based on the achievement of the Milestones, with (i) 50% of the options to vest upon the achievement of the BLA Milestone and (ii) the remaining 50% balance of the options to vest upon the achievement of the Approval Milestone, subject in each case to Mr. Cooper’s continued service as an employee of the Company on the date of each such respective Milestone.\n\nThe foregoing descriptions of the Executive Performance Option, the performance-based retention options and the performance-based retention share units are qualified in their entirety by the complete text of the Form of Performance Stock Option Agreement and Form of Performance RSU Agreement, forms of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the period ended July 31, 2026.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nENGENE THERAPEUTICS INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 18, 2026\n\nBy:\n\n/s/ Lee G. Giguere\n\n \n\n \n\n \n\nName: Lee G. Giguere\nTitle: Chief Legal Officer and Secretary"}